Company Filing History:
Years Active: 2023-2025
Title: Innovations of Hung-Tsai Kan in Cancer Regulation
Introduction
Hung-Tsai Kan is a notable inventor based in Taipei, Taiwan. He has made significant contributions to the field of cancer regulation through his innovative work on binding proteins. With a total of 2 patents, his research focuses on enhancing T cell stimulation and inhibiting cancer cell growth.
Latest Patents
Hung-Tsai Kan's latest patents include the development of PD-L1 and OX40 binding proteins for cancer regulation. These patents provide both monospecific and bispecific proteins that bind specifically to OX40 and/or PD-L1. The exemplary proteins are designed to release inhibition through PD-L1 while stimulating T cells through OX40. Additionally, the polyvalent proteins comprise at least one OX40 binding site and at least one PD-L1 binding site. In certain embodiments, these binding sites may be linked through an immunoglobulin constant region. The patents also include anti-OX40 and anti-PD-L1 antibodies.
Career Highlights
Hung-Tsai Kan is currently associated with Ap Biosciences Inc., where he continues to advance his research in cancer therapies. His work is pivotal in developing new strategies for cancer treatment, focusing on the immune system's role in combating cancer.
Collaborations
Some of his notable coworkers include Jhong-Jhe You and Ching-Hsuan Hsu, who collaborate with him on various projects related to cancer regulation.
Conclusion
Hung-Tsai Kan's innovative contributions to cancer regulation through his patents on binding proteins highlight the potential for new therapeutic approaches in oncology. His work continues to inspire advancements in cancer treatment and research.